Advice for Community Oncologists who Treat Patients with NSCLC
Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.
Potential Shift of KRASG12C Inhibitors to the Front-line Setting
Two experts discuss the potential role of using adagrasib and sotorasib in the front-line setting and how it might shift the treatment paradigm for patients with KRASG12C-mutated NSCLC with CNS metastases.
Use of Sotorasib in Patients with KRASG12C mutated NSCLC
Drs Socinski and Sabari comment on the use of sotorasib in patients with KRASG12C-mutated NSCLC with brain metastases and review data from the CodeBreak 100 and CodeBreak 200 trials.
Review of KRYSTAL 1b and Role of Adagrasib in Patients With Untreated CNS Metastases
Mark Socinski, MD and Joshua Sabari, MD review the key efficacy data from the KRYSTAL 1b cohort and discusses strategies for managing adverse events seen with adagrasib.
KRASG12C Mutations and CNS Metastases in Patients with NSCLC
Drs Socinski and Sabari discuss the emergence of the KRAS12C mutation, specifically in patients with CNS metastases and how this factors into their treatment decision.
Different Types of Biomarker Testing Methods Used in Patients with NSCLC
Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.
Importance of Biomarker Testing in Patients with NSCLC
Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.
Roundtable Discussion: Durvalumab Regimen Shows Efficacy in NSCLC
The PACIFIC study included patients with good performance status and unresectable, stage III NSCLC who did not progress after definitive platinum-based chemotherapy with concurrent radiation.
2 Commerce Drive Cranbury, NJ 08512